Boston‑based West View Capital Partners has taken a minority stake in New Jersey life‑sciences consultancy Helio Health Group. Founded in 2015, Helio offers compliance, government pricing and AI‑driven commercial software to pharma and biotech firms. The transaction aligns Helio with a wave of private‑equity backing for firms that help drug makers navigate pricing scrutiny.

West View, launched in 2004, focuses on middle‑market companies across healthcare technology and outsourcing. Its strategy embraces minority and majority recapitalizations, growth financing and roll‑up transactions. The firm’s Boston base also provides proximity to a dense cluster of digital‑health startups, enhancing deal‑sourcing opportunities. Backing Helio signals confidence that compliance‑heavy services combined with AI tools will capture expanding budgets as developers seek faster regulatory pathways.

Terms of the financing were not disclosed, but the partnership could give Helio access to West View’s network of industry contacts and capital for product development. The infusion may also fund expansion of Helio’s AI platform, positioning it to compete with larger vendors that dominate the compliance software market. Investors may view the move as validation of niche consultancies that blend regulatory expertise with data‑science, a segment that has attracted heightened M&A interest in recent quarters.